DK2646011T3 - Fremgangsmåder til reduktion af overspisning eller tvangsspisning - Google Patents

Fremgangsmåder til reduktion af overspisning eller tvangsspisning

Info

Publication number: DK2646011T3
Authority: DK; Denmark
Prior art keywords: eating; forcing; methods; reducing over; reducing
Prior art date: 2010-12-03

Application number

DK11844637.6T

Other languages

English (en)

Inventor

Eduardo Dunayevich

Susan Mcelroy

Ron Landbloom

Original Assignee

Orexigen Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-02

Publication date

2017-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2646011(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-02 Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc

2017-11-20 Application granted granted Critical

2017-11-20 Publication of DK2646011T3 publication Critical patent/DK2646011T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)

DK11844637.6T 2010-12-03 2011-12-02 Fremgangsmåder til reduktion af overspisning eller tvangsspisning DK2646011T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41935410P	2010-12-03	2010-12-03
PCT/US2011/063170 WO2012075453A1 (en)	2010-12-03	2011-12-02	Methods for reducing binge or compulsive eating

Publications (1)

Publication Number	Publication Date
DK2646011T3 true DK2646011T3 (da)	2017-11-20

Family

ID=46172302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11844637.6T DK2646011T3 (da)	2010-12-03	2011-12-02	Fremgangsmåder til reduktion af overspisning eller tvangsspisning

Country Status (27)

Country	Link
US (2)	US20130252995A1 (da)
EP (1)	EP2646011B1 (da)
JP (1)	JP2014508717A (da)
KR (1)	KR20140035319A (da)
CN (1)	CN103298462A (da)
AR (2)	AR084093A1 (da)
AU (3)	AU2011336298B2 (da)
BR (1)	BR112013015957B1 (da)
CA (1)	CA2819003A1 (da)
CL (1)	CL2013001565A1 (da)
CY (1)	CY1119560T1 (da)
DK (1)	DK2646011T3 (da)
ES (1)	ES2647232T3 (da)
HR (1)	HRP20171678T1 (da)
HU (1)	HUE034641T2 (da)
IL (1)	IL226483A0 (da)
LT (1)	LT2646011T (da)
MX (1)	MX350304B (da)
NO (1)	NO2646011T3 (da)
PL (1)	PL2646011T3 (da)
PT (1)	PT2646011T (da)
RS (1)	RS56548B1 (da)
RU (1)	RU2620913C2 (da)
SI (1)	SI2646011T1 (da)
SM (1)	SMT201700537T1 (da)
TW (2)	TW201735912A (da)
WO (1)	WO2012075453A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2316456T (pt)	2003-04-29	2017-09-05	Orexigen Therapeutics Inc	Composições para afetar a perda de peso compreendendo naltrexona e bupropion
WO2007067341A2 (en)	2005-11-22	2007-06-14	Orexigen Therapeutics, Inc.	Compositions and methods for increasing insulin sensitivity
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
EP2303025A4 (en)	2008-05-30	2012-07-04	Orexigen Therapeutics Inc	METHOD FOR TREATING DIGITAL FAT SWITCHES
JP6196041B2 (ja)	2010-01-11	2017-09-13	オレキシジェン・セラピューティクス・インコーポレーテッド	大うつ病を有する患者において減量療法を提供する方法
RS60682B1 (sr)	2012-06-06	2020-09-30	Nalpropion Pharmaceuticals Llc	Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2197250C2 (ru) *	2000-10-30	2003-01-27	Соколовский Сергей Ростиславович	Способ лечения наркоманий
PT2316456T (pt)	2003-04-29	2017-09-05	Orexigen Therapeutics Inc	Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
KR101971218B1 (ko)	2006-11-09	2019-08-27	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
GB2447949B (en) *	2007-03-29	2010-03-31	Renasci Consultancy Ltd	A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) *	2007-09-13	2009-03-19	Sanfilippo Louis C	Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2009080691A2 (en) *	2007-12-20	2009-07-02	Neurosearch A/S	Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
KR102385359B1 (ko) *	2010-11-08	2022-04-11	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

2011
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en active Application Filing
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 SM SM20170537T patent/SMT201700537T1/it unknown
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Withdrawn
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown

Also Published As

Publication number	Publication date
RU2013127420A (ru)	2015-01-10
LT2646011T (lt)	2017-11-10
ES2647232T3 (es)	2017-12-20
AU2018203921A1 (en)	2018-06-21
CY1119560T1 (el)	2018-03-07
AU2017202793A1 (en)	2017-05-18
KR20140035319A (ko)	2014-03-21
TWI536986B (zh)	2016-06-11
PT2646011T (pt)	2017-11-17
JP2014508717A (ja)	2014-04-10
SMT201700537T1 (it)	2018-01-11
MX350304B (es)	2017-09-04
AU2011336298B2 (en)	2017-03-02
MX2013006070A (es)	2013-07-29
TW201735912A (zh)	2017-10-16
US20130252995A1 (en)	2013-09-26
RS56548B1 (sr)	2018-02-28
NO2646011T3 (da)	2018-01-13
SI2646011T1 (en)	2018-01-31
BR112013015957A2 (pt)	2019-10-29
EP2646011A4 (en)	2014-04-23
CA2819003A1 (en)	2012-06-07
HRP20171678T1 (hr)	2017-12-15
PL2646011T3 (pl)	2018-01-31
AR084093A1 (es)	2013-04-17
CL2013001565A1 (es)	2014-04-04
TW201228659A (en)	2012-07-16
WO2012075453A1 (en)	2012-06-07
EP2646011B1 (en)	2017-08-16
RU2620913C2 (ru)	2017-05-30
EP2646011A1 (en)	2013-10-09
IL226483A0 (en)	2013-07-31
BR112013015957B1 (pt)	2021-07-20
US20210283126A1 (en)	2021-09-16
AU2011336298A1 (en)	2013-07-11
AU2017202793B2 (en)	2018-03-08
HUE034641T2 (en)	2018-02-28
AR124497A2 (es)	2023-04-05
CN103298462A (zh)	2013-09-11

Publication	Publication Date	Title
BR112012015988A2 (pt)	2017-06-06	método
DK2553113T3 (da)	2022-01-24	FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2534373T3 (da)	2014-08-04	Sektionsopdelt vinge
DK2622532T3 (da)	2020-03-23	Fremgangsmåde til kollaborativ beregning
BR112014010450A2 (pt)	2017-04-18	composição e método
BR112012027159A2 (pt)	2017-07-18	estrutura e método
DK2555704T3 (da)	2019-08-05	Visning af hæmostatiske parametre
BR112014003758A2 (pt)	2017-06-20	estrutura de edifício e edifício
CO6980141A1 (es)	2014-06-27	Compuestos y composiciones de poliglicerilo catónicos
DK3141548T3 (da)	2020-07-06	Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3372280T3 (da)	2020-11-16	Forbedringer af eller vedrørende synsevnen
DK2782565T3 (da)	2020-01-02	Anvendelse af aryl- og hetarylcarboxamider som endoparasiticider
DK3581199T3 (da)	2023-09-04	Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2646011T3 (da)	2017-11-20	Fremgangsmåder til reduktion af overspisning eller tvangsspisning
PL3299356T3 (pl)	2022-04-04	Sposób wytwarzania pleuromutylin
DK2627656T3 (da)	2014-09-08	Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
PT2736340T (pt)	2018-03-22	Biocontrolo de nemátodos
BR112012023743A2 (pt)	2015-09-15	formas polimórficas st-246 e métodos de preparação
BR112013009024A2 (pt)	2016-07-12	método
BR112012023891A2 (pt)	2017-12-05	método
EP2530464A4 (en)	2012-12-05	METHOD FOR MEASURING -AMYLOID
ITTO20110268A1 (it)	2011-09-30	Composizione di maquillage.
DK3067219T3 (da)	2021-06-14	Fremgangsmåde til fremstilling af paneler
BR112014010860A2 (pt)	2017-05-02	composição e método
CU24148B1 (es)	2016-02-29	Intermedios de agomelatina y método de preparación de éstos